According to a 2022 review, gastrointestinal side effects, including constipation, were among the most commonly reported adverse effects of GLP-1 receptor agonists, especially during the dose-escalation phase in about 25-35% of users
Weight loss with behavioural interventions often plateaus at a level of 5%10% and is associated with a high risk of relapse, which may be related to metabolic adaptation
Although there appears to be a high degree of overlap in GLP-1R expression in the rodent and non-human primate brain, one notable difference may be an apparent higher expression of GLP-1R in the central amygdala and bed nucleus of the stria terminalis of non-human primates (86)
beans, lentils) Nuts and seeds (e.g
While brief temperature excursions may not immediately destroy the medication, cumulative exposure to heat accelerates degradation
About 20-40% of people experience nausea, particularly during the first few weeks at each new dose